LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

Strona główna・Stock List・Puma Biotechnology Inc

Puma Biotechnology Inc

Open

SectorHealthcare

6.91 -1

Buy Sell

Overview

Share price change

24h

Current

Min

6.77

Max

7.01

Key metrics
By Trading Economics
Income	-16M -3.8M
Sales	-31M 45M
P/E Sector Avg	14.833 49.888
EPS	-0.04
Profit margin	-8.375
Employees	179
EBITDA	-28M -1.3M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-28.88% downside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	-21M 362M
Previous open	7.91
Previous close	6.91

News Sentiment

By Acuity

50%

161 / 344 Ranking in Healthcare

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 cze 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 cze 2026, 15:41 UTC

Major Market Movers

American Battery Shares Jump on Energy Department Victory

8 cze 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 cze 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 cze 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 cze 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 cze 2026, 21:57 UTC

Acquisitions, Mergers, Takeovers

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 cze 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

Salesforce Agrees to Buy m3ter

8 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 cze 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 cze 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 cze 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 cze 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 cze 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 cze 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 cze 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 cze 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 cze 2026, 16:55 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 cze 2026, 16:54 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 cze 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 cze 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 cze 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 cze 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 cze 2026, 16:03 UTC

Acquisitions, Mergers, Takeovers

Orange Bought Stake From Lorca

8 cze 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 cze 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Acquires 100% Ownership of MasOrange

8 cze 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 cze 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 cze 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 cze 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-28.88% downside

12 Months Forecast

Average 5 USD -28.88%

High 5 USD

Low 5 USD

Based on 1 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Puma Biotechnology Inc - Dist in the past 3 months.

Sentiment

By Acuity

161 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.